Single-cell Multi-omics MRD (scMRD) Assay for AML

Helping AML labs gain access to Mission Bio’s Tapestri scMRD technology

Measurable residual disease (MRD) detection using next-generation sequencing (NGS) has allowed for a sensitive evaluation of a patient's relapse risk, but several challenges remain unresolved. Bulk NGS alone provides limited sensitivity and specificity to deconstruct the complex heterogeneity/somatic mosaicism driving disease transformation or to distinguish between leukemic clones and clonal hematopoiesis (CH). It also lacks information about immunophenotypic heterogeneity, typically inferred by flow cytometry, rendering an incomplete picture.

Mission Bio's Tapestri Platform is the first single-cell multi-omics approach integrating molecular (mutational) profiling and immunophenotyping in a single assay to allow for scMRD detection with unparalleled resolution, sensitivity and specificity, ultimately improving identification of residual disease and potential therapeutic strategies

Tapestri Platform resolves several challenges in MRD testing:

Unmask clonal architecture at diagnosis and during treatment and detect rare and subclonal variants driving the disease transformation

Characterize changes in clonal diversity over time, providing valuable information about tumor evolution and its correlation with relapse

Enable unambiguous distinction between leukemia driving clones and CH, reducing false positives

Integrate single-cell genotypic and immunophenotypic information for a comprehensive MRD assessment

Interested in learning more about our scMRD technology? Join us on September 9-13 in Paris, France at ESMO Congress 2022.

Mission Bio will be attending ESMO Congress 2022 in Paris, France on September 9-13. Join Todd Druley, Aaron Llanso, Blake Alexander, Metamia Ciampricotti, and Simone Formisano to learn more about the scMRD early access program as well as to uncover opportunities to implement single-cell multi-omics into your research/clinical program.

Let's Meet at ESMO Congress 2022

Complete the form below to request a meeting and we'll be in touch within 24 hours.

Read our GDPR insert in our Privacy Policy